BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32666469)

  • 21. Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan.
    Yanagisawa R; Nakazawa Y; Matsuda K; Yasumi T; Kanegane H; Ohga S; Morimoto A; Hashii Y; Imaizumi M; Okamoto Y; Saito AM; Horibe K; Ishii E;
    Int J Hematol; 2019 Feb; 109(2):206-213. PubMed ID: 30535855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan.
    Ohga S; Kudo K; Ishii E; Honjo S; Morimoto A; Osugi Y; Sawada A; Inoue M; Tabuchi K; Suzuki N; Ishida Y; Imashuku S; Kato S; Hara T
    Pediatr Blood Cancer; 2010 Feb; 54(2):299-306. PubMed ID: 19827139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignancy-associated hemophagocytic lymphohistiocytosis in children: a 10-year experience of a single pediatric hematology center.
    Huang Z; Jia Y; Zuo Y; Wu J; Lu A; Zhang L
    Hematology; 2020 Dec; 25(1):389-399. PubMed ID: 33161882
    [No Abstract]   [Full Text] [Related]  

  • 24. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
    Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis].
    Wang Y; Huang W; Wei N; Zeng X; Zhang J; Wang J; Wu L; Fu L; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Oct; 35(10):901-4. PubMed ID: 25339326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
    Ma H; Zhang R; Zhang L; Wei A; Zhao X; Yang Y; Liu W; Li Z; Qin M; Wang T
    Ann Hematol; 2020 Oct; 99(10):2255-2263. PubMed ID: 32766934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
    Huang Z; Xie J
    Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults.
    Liu P; Pan X; Chen C; Niu T; Shuai X; Wang J; Chen X; Liu J; Guo Y; Xie L; Wu Y; Liu Y; Liu T
    Blood; 2020 Mar; 135(11):826-833. PubMed ID: 31914172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
    Trantham T; Auten J; Muluneh B; Van Deventer H
    J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.
    Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG
    Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
    Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA
    Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
    Sin JH; Zangardi ML
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus-related hemophagocytic lymphohistiocytosis complicated with coronary artery dilation and acute renal injury in a boy with a novel X-linked inhibitor of apoptosis protein (XIAP) variant: a case report.
    Chen RY; Li XZ; Lin Q; Zhu Y; Shen YY; Xu QY; Zhu XM; Bai ZJ; Li Y
    BMC Pediatr; 2020 Oct; 20(1):456. PubMed ID: 33008347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children: a systematic review and meta analysis.
    Qin Q; Xie Z; Shen Y; Yang S; Liu C; Huang Z; Xu J; Al J; Shen K
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):672-8. PubMed ID: 22774410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children.
    Pan H; Wang G; Guan E; Song L; Song A; Liu X; Yi Z; Sun LR
    BMC Pediatr; 2020 Jun; 20(1):288. PubMed ID: 32517812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
    Keenan C; Nichols KE; Albeituni S
    Front Immunol; 2021; 12():614704. PubMed ID: 33664745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol.
    Yanagaisawa R; Matsuda K; Ohga S; Kanegane H; Morimoto A; Okamoto Y; Ohara A; Fukushima K; Sotomatsu M; Nomura K; Saito AM; Horibe K; Ishii E; Nakazawa Y
    Int J Hematol; 2019 May; 109(5):612-617. PubMed ID: 30788725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-94 protocol.
    Lee JS; Kang JH; Lee GK; Park HJ
    J Korean Med Sci; 2005 Apr; 20(2):209-14. PubMed ID: 15831988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.
    Yao S; He L; Zhang R; Liu M; Hua Z; Zou H; Wang Z; Wang Y
    Ann Med; 2023 Dec; 55(1):89-100. PubMed ID: 36533966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.